米拉贝隆联合坦索罗辛治疗BPH伴OAB症状的安全性分析
本文为随机4期PLUS研究的安全性分析,纳入352例坦索罗辛联合米拉贝隆(TAM+MIRA)和354例坦索罗辛联合安慰剂(TAM+PL)的男性患者。结果显示联合治疗未发现非预期安全性问题,两组血压、脉率及心电图参数无重大变化,残余尿量和最大尿流率(Qmax)的变化无临床意义。
要点
- 联合治疗未发现非预期安全性问题
- 两组血压、脉率及心电图参数无重大变化
- 残余尿量与Qmax变化无临床意义
核心结论
- 在因BPH相关下尿路症状接受坦索罗辛治疗的男性中,后续加用米拉贝隆未发现非预期安全性问题。
研究设计与样本
- 4期PLUS研究为随机对照试验,含4周导入期(坦索罗辛0.4 mg)和12周随机治疗期(加用米拉贝隆25 mg或安慰剂,4周后增至米拉贝隆50 mg或匹配安慰剂)。
- 安全性分析集包括352例TAM+MIRA和354例TAM+PL患者。
主要发现
- 总体治疗中出现的不良事件(TEAE)频率TAM+PL更高,但药物相关TEAE在TAM+MIRA发生率更高。
- 大多数TEAE为轻或中度。
- 药物相关严重TEAE报告于3例患者(TAM+MIRA 2例:急性心肌梗死伴脑梗死及心绞痛;TAM+PL 1例:腔隙性卒中)。
- 高血压、头痛和鼻咽炎为最常见TEAE。
- 特别关注TEAE少见,最常见为尿潴留,2例TAM+MIRA患者需导尿(均未导致停药)。
关键数值与推荐
- 两组血压或脉率无重大变化,心电图参数相似。
- 平均残余尿量和Qmax的变化无临床意义。
临床怎么用
- 对于BPH相关下尿路症状且已使用坦索罗辛的男性,加用米拉贝隆的安全性数据支持其临床应用,但仍需关注药物相关不良事件及个别严重事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the safety of mirabegron add-on therapy in men with overactive bladder symptoms concurrently receiving tamsulosin for lower urinary tract symptoms associated with benign prostatic hyperplasia. METHODS: The Phase 4 PLUS study comprised a 4-week run-in period (tamsulosin [0.4 mg]) and a 12-week randomized treatment period (add-on treatment: mirabegron [25 mg] or placebo). Doses were increased to mirabegron 50 mg or matched placebo after 4 weeks. Safety assessments: treatment-emergent adverse events (TEAEs), vital signs, 12-lead electrocardiograms, and changes in postvoid residual volume and maximum urinary flow (Qmax). RESULTS: The safety analysis set included 352 tamsulosin plus mirabegron (TAM + MIRA) and 354 tamsulosin plus placebo (TAM + PL) patients. The frequency of overall TEAEs was higher with TAM + PL, although a higher incidence of drug-related TEAEs was observed with TAM + MIRA. Most TEAEs were mild or moderate in severity. Drug-related serious TEAEs were reported for 3 patients (2 TAM + MIRA patients: acute myocardial infarction with cerebral infarction and angina pectoris, 1 TAM + PL patient: lacunar stroke). Hypertension, headache, and nasopharyngitis were the most common TEAEs. Special interest TEAEs were infrequently reported. The most common was urinary retention and 2 TAM + MIRA patients required catheterization (neither led to discontinuation). No major changes in blood pressure or pulse rate were noted and similar electrocardiogram parameters were observed for both groups. Changes in mean postvoid residual volume and Qmax were not clinically meaningful. CONCLUSION: No unexpected safety concerns were noted in men receiving tamsulosin for lower urinary tract symptoms associated with benign prostatic hyperplasia who subsequently received mirabegron add-on therapy.
引用
- Herschorn S, McVary KT, Cambronero Santos J, et al. Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study. Urology. 2020. PMID: 33045287. doi:10.1016/j.urology.2020.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。